Document is current
Any future updates will be listed below
-
Authors
Fiskin, Evgenij
Eraslan, Gökcen https://orcid.org/0000-0001-9579-2909
Alora-Palli, Maria B.
Jain, Tanvi
Leyva-Castillo, Juan Manuel https://orcid.org/0000-0001-7394-4457
Kim, Sean
Choe, Heather
Lareau, Caleb A.
Lau, Helena
Finan, Emily P.
Teixeira-Soldano, Isabella
LaBere, Brenna
Chu, Anne
Woods, Brian
Chou, Janet
Slyper, Michal
Waldman, Julia https://orcid.org/0000-0002-0584-5833
Islam, Sabina
Schneider, Lynda
Phipatanakul, Wanda
Platt, Craig https://orcid.org/0000-0002-1901-4563
Rozenblatt-Rosen, Orit https://orcid.org/0000-0001-6313-3570
Delorey, Toni M. https://orcid.org/0000-0001-6614-3803
Ashenberg, Orr
Deguine, Jacques https://orcid.org/0000-0001-9218-3040
Smith, Gideon P.
Geha, Raif S.
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Xavier, Ramnik J. https://orcid.org/0000-0002-5630-5167
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (DK114784)
- License Information
-
More Information
Article History
Received: 4 August 2025
Accepted: 30 January 2026
First Online: 25 February 2026
Competing interests
: A.R. was a founder and equity holder of Celsius Therapeutics, is an equity holder in Immunitas Therapeutics, and until 31 July 2020 was an SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov, and ThermoFisher Scientific. From 1 August 2020, A.R. is an employee of Genentech, a member of the Roche Group, with equity in Roche. R.J.X. is a co-founder of Celsius Therapeutics, Jnana Therapeutics, and director of Moonlake Immunotherapeutics. R.J.X. is an SAB member of Magnet Biomedicine and of Nestlé. From 19 October 2020 to 4 April 2022, respectively, O.R.-R. and G.E. are employees of Genentech, a member of the Roche Group, and have equity in Roche. The remaining authors declare no competing interests.
